By Jeffrey N. Gibbs and David A. Gibbs* – FDA’s premarket approval (PMA) advisory panels are high visibility events. Both FDA and companies invest heavily in preparing for these meetings. Thus, when the rules governing PMA panel meetings change, it should be big news. Yet, when FDA …
Menu